Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial

NCT07732218 | Completed Phase 4

• 1 other identifier: Semaglutide 1
• Study Type: interventional
• Target: 95
• Locations: 1 country
• Sites: 1

Brief Summary

A single arm no randomized clinical trial evaluated the effectiveness and safety of once weekly semaglutide in adults with type 2 diabetes militus and obesity whose glycemic control remained inadequate despite standard therapy. participants received semaglutide for 16 weeks, beginning with 0.25mg weekly for 4 weeks followed by 0.5 mg weekly for 12 weeks. the primary outcome was the change in glycated hemoglobin, while secondary outcomes included changes in body weight, body mass index, blood glucose, blood pressure, lipid profile and treatment related adverse effects.

Conditions

Type 2 Diabetes

Keywords

Semaglutide; type 2 diabetes mellitus;Obesity;Glycemic Control; HbA1c; GLP-1 Receptor Agonist

Outcome Measures

Primary Outcomes (2)

• Change in Glycated hemoglobin

  Absolute change in hemoglobin from baseline to end of 16 weeks once weekly semaglutide treatment

  baseline and 16 week

• Changes in Glycated Hemoglobin

  Absolute change in HBA1c from baseline to the end of 16 weeks of once weekly semaglutide treatment.

  Baseline and week 16

Secondary Outcomes (4)

• Changes in body weight

  baseline to week 16

• Changes in BMI

  rom baseline to week 16

• Changes in fasting Blood Glucose

  baseline to week 16

• Change in random blood glucose

  Baseline to week 16

Study Arms (1)

Once-weekly Semaglutide

EXPERIMENTAL

participants received subcutaneous semaglutide 0.25mg once weekly for 4 weeks followed by 0.5mg once weekly for 12 weeks, for a total treatment duration of 16 weeks

Drug: Semaglutide (Ozempic®)

Interventions

Semaglutide (Ozempic®) DRUG

participants received semaglutide by subcutaneous injection once weekly for 16 weeks. smaglutide was initiated at 0.25mg once weekly for the first 4 weeks, followed by 0.5mg once weekly for the subsequent 12 weeks

Once-weekly Semaglutide

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 18 years or older. Established diagnosis of type 2 diabetes mellitus for at least 6 months. Glycated hemoglobin (HbA1c) between 7.5% and 10.0%. Body mass index (BMI) of at least 30 kg/m². Inadequate glycemic control despite ongoing standard diabetes therapy. Willing and able to provide written informed consent.

You may not qualify if:

• Type 1 diabetes mellitus. Gestational diabetes mellitus. Severe renal impairment, defined as an estimated glomerular filtration rate of 30 mL/min/1.73 m² or less.
• Previous or current treatment with any glucagon-like peptide-1 receptor agonist.
• History of chronic pancreatitis. History of pancreatic malignancy. Diabetic retinopathy requiring active treatment. Other significant ocular complications. Pregnancy or lactation. Known thyroid disorders. History or presence of thyroid neoplasms.

Sponsors & Collaborators

• Rehman Medical Institute - RMI: lead

Study Sites (1)

Rehman Medical Institute

Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: July 23, 2026
• First Posted: July 28, 2026
• Study Start: July 4, 2022
• Primary Completion: March 30, 2023
• Study Completion: March 30, 2023
• Last Updated: July 28, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)